| 3801 |
Apheresis |
Allogeneic |
Acute Myeloid Leukemia |
Hematology |
2021 |
Standard Therapy |
Poland |
32 |
| 3802 |
Apheresis |
Allogeneic |
Acute Myeloid Leukemia |
Hematology |
2021 |
Standard Therapy |
Poland |
61 |
| 3803 |
Apheresis |
Allogeneic |
Acute Myeloid Leukemia |
Hematology |
2021 |
Standard Therapy |
Poland |
64 |
| 3804 |
Apheresis |
Allogeneic |
Acute Myeloid Leukemia |
Hematology |
2021 |
Standard Therapy |
Poland |
10 |
| 3805 |
Apheresis |
Allogeneic |
Acute Myeloid Leukemia |
Hematology |
2021 |
Standard Therapy |
Poland |
67 |
| 3806 |
Apheresis |
Allogeneic |
Acute Myeloid Leukemia |
Hematology |
2021 |
Standard Therapy |
Poland |
57 |
| 3807 |
Apheresis |
Allogeneic |
Acute Myeloid Leukemia |
Hematology |
2021 |
Standard Therapy |
Poland |
55 |
| 3808 |
Apheresis |
Allogeneic |
Acute Myeloid Leukemia |
Hematology |
2021 |
Standard Therapy |
Poland |
68 |
| 3809 |
Apheresis |
Allogeneic |
Acute Myeloid Leukemia |
Hematology |
2021 |
Standard Therapy |
Poland |
61 |
| 3810 |
Apheresis |
Allogeneic |
Acute Myeloid Leukemia |
Hematology |
2021 |
Standard Therapy |
Poland |
17 |
| 3811 |
Apheresis |
Allogeneic |
Acute Myeloid Leukemia |
Hematology |
2021 |
Standard Therapy |
Poland |
46 |
| 3812 |
Apheresis |
Allogeneic |
Acute Myeloid Leukemia |
Hematology |
2021 |
Standard Therapy |
Poland |
34 |
| 3813 |
Apheresis |
Allogeneic |
Acute Myeloid Leukemia |
Hematology |
2021 |
Standard Therapy |
Poland |
39 |
| 3814 |
Apheresis |
Allogeneic |
Acute Myeloid Leukemia |
Hematology |
2021 |
Standard Therapy |
Poland |
53 |
| 3815 |
Apheresis |
Allogeneic |
Acute Myeloid Leukemia |
Hematology |
2021 |
Standard Therapy |
Poland |
63 |
| 3816 |
Apheresis |
Allogeneic |
Acute Myeloid Leukemia |
Hematology |
2021 |
Standard Therapy |
Poland |
22 |
| 3817 |
Apheresis |
Allogeneic |
Acute Myeloid Leukemia |
Hematology |
2021 |
Standard Therapy |
Poland |
56 |
| 3818 |
Apheresis |
Allogeneic |
Acute Myeloid Leukemia |
Hematology |
2021 |
Standard Therapy |
Poland |
42 |
| 3819 |
Apheresis |
Allogeneic |
Acute Myeloid Leukemia |
Hematology |
2021 |
Standard Therapy |
Poland |
66 |
| 3820 |
Apheresis |
Allogeneic |
Acute Myeloid Leukemia |
Hematology |
2021 |
Standard Therapy |
Poland |
52 |
| 3821 |
Apheresis |
Allogeneic |
Acute Myeloid Leukemia |
Hematology |
2021 |
Standard Therapy |
Poland |
13 |
| 3822 |
Apheresis |
Allogeneic |
Acute Myeloid Leukemia |
Hematology |
2021 |
Standard Therapy |
Germany |
32 |
| 3823 |
Apheresis |
Allogeneic |
Acute Myeloid Leukemia |
Hematology |
2021 |
Standard Therapy |
Germany |
61 |
| 3824 |
Apheresis |
Allogeneic |
Acute Myeloid Leukemia |
Hematology |
2021 |
Standard Therapy |
Germany |
72 |
| 3825 |
Apheresis |
Allogeneic |
Acute Myeloid Leukemia |
Hematology |
2021 |
Standard Therapy |
Germany |
55 |
| 3826 |
Apheresis |
Allogeneic |
Acute Myeloid Leukemia |
Hematology |
2021 |
Standard Therapy |
Germany |
57 |
| 3827 |
Apheresis |
Allogeneic |
Acute Myeloid Leukemia |
Hematology |
2021 |
Standard Therapy |
Germany |
62 |
| 3828 |
Apheresis |
Allogeneic |
Acute Myeloid Leukemia |
Hematology |
2021 |
Standard Therapy |
Germany |
46 |
| 3829 |
Apheresis |
Allogeneic |
Acute Myeloid Leukemia |
Hematology |
2021 |
Standard Therapy |
Germany |
63 |
| 3830 |
Apheresis |
Allogeneic |
Acute Myeloid Leukemia |
Hematology |
2021 |
Standard Therapy |
Germany |
65 |
| 3831 |
Apheresis |
Allogeneic |
Acute Myeloid Leukemia |
Hematology |
2021 |
Standard Therapy |
Germany |
71 |
| 3832 |
Apheresis |
Allogeneic |
Acute Myeloid Leukemia |
Hematology |
2021 |
Standard Therapy |
Germany |
53 |
| 3833 |
Apheresis |
Allogeneic |
Acute Myeloid Leukemia |
Hematology |
2021 |
Standard Therapy |
Germany |
57 |
| 3834 |
Apheresis |
Allogeneic |
Acute Myeloid Leukemia |
Hematology |
2021 |
Standard Therapy |
Germany |
50 |
| 3835 |
Apheresis |
Allogeneic |
Acute Myeloid Leukemia |
Hematology |
2021 |
Standard Therapy |
Germany |
32 |
| 3836 |
Apheresis |
Allogeneic |
Acute Myeloid Leukemia |
Hematology |
2021 |
Standard Therapy |
Germany |
71 |
| 3837 |
Apheresis |
Allogeneic |
Acute Myeloid Leukemia – Relapse |
Hematology |
2021 |
Standard Therapy |
Germany |
65 |
| 3838 |
Apheresis |
Autologous |
Amyloidosis |
Hematology |
2021 |
Standard Therapy |
Germany |
63 |
| 3839 |
Apheresis |
Allogeneic |
Anaplastic Large Cell Lymphoma |
Hematology |
2021 |
Standard Therapy |
Germany |
56 |
| 3840 |
Apheresis |
Autologous |
Angioimmunoblastic T-Cell Lymphoma |
Hematology |
2021 |
Standard Therapy |
Germany |
62 |
| 3841 |
Apheresis |
Allogeneic |
Aplastic Anemia |
Hematology |
2021 |
Standard Therapy |
Poland |
54 |
| 3842 |
Apheresis |
Allogeneic |
Aplastic Anemia |
Hematology |
2021 |
Standard Therapy |
Poland |
7 |
| 3843 |
Apheresis |
Allogeneic |
Aplastic Anemia |
Hematology |
2021 |
Standard Therapy |
Poland |
40 |
| 3844 |
Apheresis |
Allogeneic |
Aplastic Anemia |
Hematology |
2021 |
Standard Therapy |
Poland |
14 |
| 3845 |
Apheresis |
Allogeneic |
B-Cell Acute Lymphoblastic Leukemia |
Hematology |
2021 |
Standard Therapy |
Poland |
36 |
| 3846 |
Apheresis |
Autologous |
B-Cell Lymphoma |
Hematology |
2021 |
Standard Therapy |
Germany |
59 |
| 3847 |
Apheresis |
Autologous |
B-Cell Lymphoma |
Hematology |
2021 |
Standard Therapy |
Germany |
33 |
| 3848 |
Apheresis |
Autologous |
B-Cell Lymphoma |
Hematology |
2021 |
Standard Therapy |
Germany |
63 |
| 3849 |
Apheresis |
Autologous |
B-Cell Lymphoma |
Hematology |
2021 |
Standard Therapy |
Germany |
49 |
| 3850 |
Apheresis |
Allogeneic |
Chronic Granulomatous Disease |
Hematology |
2021 |
Standard Therapy |
Poland |
28 |
| 3851 |
Apheresis |
Allogeneic |
Chronic Granulomatous Disease |
Hematology |
2021 |
Standard Therapy |
Poland |
11 |
| 3852 |
Apheresis |
Allogeneic |
Chronic Lymphocytic Leukemia |
Hematology |
2021 |
Standard Therapy |
Poland |
62 |
| 3853 |
Apheresis |
Allogeneic |
Chronic Lymphocytic Leukemia |
Hematology |
2021 |
Standard Therapy |
Poland |
60 |
| 3854 |
Apheresis |
Allogeneic |
Chronic Lymphocytic Leukemia |
Hematology |
2021 |
Standard Therapy |
Poland |
63 |
| 3855 |
Apheresis |
Allogeneic |
Chronic Myelogenous Leukemia |
Hematology |
2021 |
Standard Therapy |
Poland |
52 |
| 3856 |
Apheresis |
Allogeneic |
Chronic Myelogenous Leukemia |
Hematology |
2021 |
Standard Therapy |
Poland |
45 |
| 3857 |
Apheresis |
Allogeneic |
Chronic Myelogenous Leukemia |
Hematology |
2021 |
Standard Therapy |
Poland |
37 |
| 3858 |
Apheresis |
Allogeneic |
Chronic Myelogenous Leukemia |
Hematology |
2021 |
Standard Therapy |
Poland |
62 |
| 3859 |
Apheresis |
Allogeneic |
Chronic Myelogenous Leukemia |
Hematology |
2021 |
Standard Therapy |
Poland |
64 |
| 3860 |
Apheresis |
Allogeneic |
Chronic Myelogenous Leukemia |
Hematology |
2021 |
Standard Therapy |
Poland |
74 |
| 3861 |
Apheresis |
Allogeneic |
Chronic Myelogenous Leukemia |
Hematology |
2021 |
Standard Therapy |
Poland |
31 |
| 3862 |
Apheresis |
Allogeneic |
Chronic Myelogenous Leukemia |
Hematology |
2021 |
Standard Therapy |
Poland |
63 |
| 3863 |
Apheresis |
Allogeneic |
Chronic Myelogenous Leukemia |
Hematology |
2021 |
Standard Therapy |
Poland |
18 |
| 3864 |
Apheresis |
Allogeneic |
Chronic Myelomonocytic Leukemia |
Hematology |
2021 |
Standard Therapy |
Poland |
68 |
| 3865 |
Apheresis |
Allogeneic |
Chronic Myelomonocytic Leukemia |
Hematology |
2021 |
Standard Therapy |
Poland |
59 |
| 3866 |
Apheresis |
Allogeneic |
Chronic Myelomonocytic Leukemia |
Hematology |
2021 |
Standard Therapy |
Poland |
67 |
| 3867 |
Apheresis |
Allogeneic |
Chronic Myelomonocytic Leukemia |
Hematology |
2021 |
Standard Therapy |
Poland |
62 |
| 3868 |
Apheresis |
Allogeneic |
Chronic Myelomonocytic Leukemia |
Hematology |
2021 |
Standard Therapy |
Poland |
34 |
| 3869 |
Apheresis |
Allogeneic |
Chronic Myelomonocytic Leukemia |
Hematology |
2021 |
Standard Therapy |
Poland |
70 |
| 3870 |
Apheresis |
Allogeneic |
Chronic Myelomonocytic Leukemia |
Hematology |
2021 |
Standard Therapy |
Poland |
71 |
| 3871 |
Apheresis |
Allogeneic |
Chronic Neutrophilic Leukemia |
Hematology |
2021 |
Standard Therapy |
Germany |
67 |
| 3872 |
Apheresis |
Allogeneic |
Diffuse Large B-Cell Lymphoma |
Hematology |
2021 |
Standard Therapy |
Poland |
62 |
| 3873 |
Apheresis |
Allogeneic |
Diffuse Large B-Cell Lymphoma |
Hematology |
2021 |
Standard Therapy |
Poland |
50 |
| 3874 |
Apheresis |
Autologous |
Diffuse Large B-Cell Lymphoma |
Hematology |
2021 |
Standard Therapy |
Germany |
68 |
| 3875 |
Apheresis |
Autologous |
Diffuse Large B-Cell Lymphoma |
Hematology |
2021 |
Standard Therapy |
Germany |
63 |
| 3876 |
Apheresis |
Autologous |
Diffuse Large B-Cell Lymphoma – Relapse |
Hematology |
2021 |
Standard Therapy |
Germany |
65 |
| 3877 |
Apheresis |
Autologous |
Diffuse Large B-Cell Lymphoma – Relapse |
Hematology |
2021 |
Standard Therapy |
Germany |
65 |
| 3878 |
Apheresis |
Autologous |
Diffuse Large B-Cell Lymphoma – Relapse |
Hematology |
2021 |
Standard Therapy |
Germany |
71 |
| 3879 |
Apheresis |
Allogeneic |
Farber Disease |
Hematology |
2021 |
Standard Therapy |
Poland |
9 |
| 3880 |
Apheresis |
Allogeneic |
Follicular Lymphoma |
Hematology |
2021 |
Standard Therapy |
Poland |
54 |
| 3881 |
Apheresis |
Autologous |
Follicular Lymphoma |
Hematology |
2021 |
Standard Therapy |
Germany |
55 |
| 3882 |
Apheresis |
Autologous |
Follicular Lymphoma |
Hematology |
2021 |
Standard Therapy |
Germany |
64 |
| 3883 |
Apheresis |
Autologous |
Follicular Lymphoma |
Hematology |
2021 |
Standard Therapy |
Germany |
50 |
| 3884 |
Apheresis |
Autologous |
Germ Cell Tumor |
Hematology |
2021 |
Standard Therapy |
Germany |
28 |
| 3885 |
Apheresis |
Allogeneic |
Hemophagocytic Lymphohistiocytosis (Hlh) |
Hematology |
2021 |
Standard Therapy |
Poland |
23 |
| 3886 |
Apheresis |
Allogeneic |
Hodgkin Lymphoma |
Hematology |
2021 |
Standard Therapy |
Poland |
41 |
| 3887 |
Apheresis |
Allogeneic |
Hodgkin Lymphoma |
Hematology |
2021 |
Standard Therapy |
Poland |
40 |
| 3888 |
Apheresis |
Allogeneic |
Hodgkin Lymphoma |
Hematology |
2021 |
Standard Therapy |
Poland |
27 |
| 3889 |
Apheresis |
Allogeneic |
Hodgkin Lymphoma |
Hematology |
2021 |
Standard Therapy |
Poland |
19 |
| 3890 |
Apheresis |
Allogeneic |
Hodgkin Lymphoma |
Hematology |
2021 |
Standard Therapy |
Poland |
26 |
| 3891 |
Apheresis |
Allogeneic |
Hodgkin Lymphoma |
Hematology |
2021 |
Standard Therapy |
Poland |
32 |
| 3892 |
Apheresis |
Allogeneic |
Hodgkin Lymphoma |
Hematology |
2021 |
Standard Therapy |
Germany |
21 |
| 3893 |
Apheresis |
Allogeneic |
Hodgkin Lymphoma |
Hematology |
2021 |
Standard Therapy |
Germany |
37 |
| 3894 |
Apheresis |
Autologous |
Hodgkin Lymphoma |
Hematology |
2021 |
Standard Therapy |
Germany |
30 |
| 3895 |
Apheresis |
Allogeneic |
Hodgkin Lymphoma |
Hematology |
2021 |
Standard Therapy |
Germany |
47 |
| 3896 |
Apheresis |
Autologous |
Hodgkin Lymphoma |
Hematology |
2021 |
Standard Therapy |
Germany |
36 |
| 3897 |
Apheresis |
Autologous |
Hodgkin Lymphoma |
Hematology |
2021 |
Standard Therapy |
Germany |
30 |
| 3898 |
Apheresis |
Allogeneic |
Hurler Syndrome |
Hematology |
2021 |
Standard Therapy |
Poland |
2 |
| 3899 |
Apheresis |
Allogeneic |
Immunodeficiency |
Hematology |
2021 |
Standard Therapy |
Poland |
12 |
| 3900 |
Apheresis |
Allogeneic |
Leukemia |
Hematology |
2021 |
Standard Therapy |
Poland |
63 |